These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 26121975)

  • 1. Belgian experience with triple therapy with boceprevir and telaprevir in genotype 1 infected patients who inject drugs.
    Arain A; Bourgeois S; de Galocsy C; Henrion J; Deltenre P; d'Heygere F; George C; Bastens B; Van Overbeke L; Verrando R; Bruckers L; Mathei C; Buntinx F; Van Vlierberghe H; Francque S; Laleman W; Moreno C; Janssens F; Nevens F; Robaeys G
    J Med Virol; 2016 Jan; 88(1):94-9. PubMed ID: 26121975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
    Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.
    Pungpapong S; Aqel BA; Koning L; Murphy JL; Henry TM; Ryland KL; Yataco ML; Satyanarayana R; Rosser BG; Vargas HE; Charlton MR; Keaveny AP
    Liver Transpl; 2013 Jul; 19(7):690-700. PubMed ID: 23696372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients.
    Beste LA; Green PK; Ioannou GN
    Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):123-9. PubMed ID: 25503739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting.
    Mandorfer M; Payer BA; Niederecker A; Lang G; Aichelburg MC; Strassl R; Boesecke C; Rieger A; Trauner M; Peck-Radosavljevic M; Reiberger T
    AIDS Patient Care STDS; 2014 May; 28(5):221-7. PubMed ID: 24796757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Favourable SVR12 rates with boceprevir or telaprevir triple therapy in HIV/HCV coinfected patients.
    Arends JE; van der Meer JT; Posthouwer D; Kortmann W; Brinkman K; van Assen S; Smit C; van der Valk M; van der Ende M; Schinkel J; Reiss P; Richter C; Hoepelman AI; ;
    Neth J Med; 2015 Aug; 73(7):324-30. PubMed ID: 26314715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1.
    Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2012 Jul; 84(7):1097-105. PubMed ID: 22585728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
    Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
    J Hepatol; 2013 Sep; 59(3):434-41. PubMed ID: 23669289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of chronic hepatitis C with triple therapy in an opioid agonist treatment program.
    Litwin AH; Soloway IJ; Cockerham-Colas L; Reynoso S; Heo M; Tenore C; Roose RJ
    Int J Drug Policy; 2015 Oct; 26(10):1014-9. PubMed ID: 26341685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.
    Hara T; Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Kumada H
    J Med Virol; 2013 Oct; 85(10):1746-53. PubMed ID: 23861088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple therapy with boceprevir or telaprevir for prior HCV non-responders.
    Asselah T
    Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):455-62. PubMed ID: 23199504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
    Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
    J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis.
    Cure S; Diels J; Gavart S; Bianic F; Jones E
    Curr Med Res Opin; 2012 Nov; 28(11):1841-56. PubMed ID: 23016967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future perspectives: towards interferon-free regimens for HCV.
    Gane E
    Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.
    Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F;
    J Clin Virol; 2015 Dec; 73():32-35. PubMed ID: 26528903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings.
    Butt AA; Yan P; Shaikh OS; Freiberg MS; Lo Re V; Justice AC; Sherman KE;
    J Viral Hepat; 2015 Sep; 22(9):691-700. PubMed ID: 25524834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C.
    Atsukawa M; Tsubota A; Shimada N; Kondo C; Itokawa N; Nakagawa A; Fukuda T; Matsushita Y; Narahara Y; Osada Y; Yamaguchi H; Nakatsuka K; Iwakiri K; Kawamoto C; Sakamoto C
    Eur J Gastroenterol Hepatol; 2014 Jul; 26(7):781-7. PubMed ID: 24732752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice].
    Giménez-Manzorro Á; García-González X; Rodríguez-González CG; Ochoa-Palominos A; Sanjurjo-Sáez M; Clemente-Ricote G
    Gastroenterol Hepatol; 2015 Dec; 38(10):575-82. PubMed ID: 26321320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.